ProfileGDS5678 / 1417251_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 89% 90% 89% 88% 91% 82% 82% 87% 92% 92% 89% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2763191
GSM967853U87-EV human glioblastoma xenograft - Control 27.1132389
GSM967854U87-EV human glioblastoma xenograft - Control 37.2739390
GSM967855U87-EV human glioblastoma xenograft - Control 47.1264489
GSM967856U87-EV human glioblastoma xenograft - Control 56.9070688
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1362191
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8447582
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9107482
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6914687
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7180492
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.5401992
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1086689
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3256591
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1256990